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Introduction
Depression is now the leading cause of disability worldwide (1). The majority of 
people with depression are managed in primary care (2). There has been a shift in the 
understanding of depression as a discrete or episodic illness to being considered a 
long-term relapsing-remitting condition with possibly incomplete recovery between 
episodes for some patients. The literature draws a distinction between relapse (the re-
emergence of depressive symptoms following some level of remission, but preceding 
full recovery) and recurrence (the onset of a new episode of depression following 
recovery), recurrence rates being lower than relapse rates (3). This dichotomy may be 
more important to researchers and clinicians than it is to patients, who are likely to be 
less concerned with terminology and more concerned by the risk of “becoming unwell 
again” and what can be done to reduce this risk. 
After treatment of the first episode of depression, approximately half of all patients 
will relapse, and this risk increases for every subsequent episode (70% and 90% 
after a second and third episode respectively) (4). A recent study of a cohort of 
patients who had received psychosocial treatment through the Improving Access to 
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Psychological Therapies (IAPT) service (5) showed that, of those who relapse, the 
majority (79%) do so within the first six months (6). There is also evidence to suggest 
that the severity of depression and resistance to treatment increases with each 
successive episode (7), so there are potential benefits of providing on-going care 
following remission, perhaps after the first episode, to prevent relapse and improve 
overall disease trajectory. This editorial examines the current evidence around relapse 
prevention in primary care before discussing the case for improved risk-stratification 
of patients and the implications that this would have for clinical practice.
Can relapse be prevented?
There are few studies looking at relapse prevention strategies specifically in a primary 
care setting (8);  the vast majority of studies looking at relapse have been undertaken 
in secondary care.  During the development of the most recent update to the 
Depression Guideline, NICE recommends that work be done to identify individuals at 
increased risk of relapse and provide relapse prevention strategies for these 
individuals (9). 
Current relapse prevention interventions recommended by NICE are a minimum of 
two years treatment with antidepressant medication for patients who have had two or 
more episodes of depression; high-intensity mindfulness-based cognitive therapy 
(MBCT) for patients who have had three episodes or more of depression; and high-
intensity individual cognitive behavioural therapy (CBT) for patients who have 
relapsed despite antidepressant medication (10). In more severe cases, patients are 
usually referred for specialist treatment where relapse prevention interventions can 
include further high-intensity psychological treatment and lithium augmentation of 
antidepressant medication. There is some evidence that acute treatment with 
electroconvulsive therapy (ECT) and an antidepressant is more effective at preventing 
relapse rather than antidepressant medication alone, although the NICE Guideline 
Committee recognised that the evidence for this was of low quality (9). 
The availability and supply of psychological treatments as recommended by NICE is 
inadequate at present and it is possible that these interventions do not constitute 
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realistic treatment options in the real-world NHS (11). Evidence for their 
effectiveness and cost-effectiveness in a primary care setting is also lacking (9). 
Lessons need to be learned from trials of primary care-based relapse prevention 
interventions and novel feasible, scalable interventions are likely to be required to 
ensure effective implementation and improved outcomes for patients. More research 
is needed to better understand relapse prevention of depression in primary care to 
guide optimal allocation of interventions in practice.
Can relapse be predicted? 
If relapse and remission of depression could be reliably predicted at the individual 
patient-level, then resources can be better targeted towards relapse prevention of 
depression and support precision medicine, i.e., tailoring of intervention decisions 
conditional on an individual predicted risk and response to treatment (12). This 
process requires prognosis research; specifically, the identification of prognostic 
factors and the development, validation and impact evaluation of prognostic models 
for outcome risk prediction. Prognosis is “the forecast of future outcomes for people 
with a particular disease or health condition” (12). A recent systematic review 
identified several prognostic factors associated with increased risk of relapse and 
recurrence in depression including: childhood adversity; recurrent depression; 
presence of residual symptoms; comorbid anxiety; rumination; neuroticism and age of 
onset of depression (13). In the UK, NICE currently highlights only a small number 
of these (in particular, number of previous depressive episodes and presence of 
residual depression symptoms) to guide prognostication in people with depression 
(10). 
We are not yet at the point where we can reliably predict outcomes for a given patient 
with depression in primary care based on their demographic, clinical and disease-level 
characteristics. Single prognostic factors are seldom sufficient to effectively aid risk-
stratification at the individual level. Rather, individualised outcome prediction is 
better shaped by using multiple prognostic factors in combination, to create a 
multivariable prognostic model (14). Such risk prediction tools are increasingly 
recommended by policymakers and, in general practice, can be successfully built into 
IT systems (15). A robust clinical tool to risk-stratify patients and then target relapse 
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prevention interventions to those at increased risk would be of significant benefit to 
patients, healthcare professionals and the NHS as a whole.
Implications for patients and practice
Improving risk-stratification and the allocation of relapse prevention interventions in 
primary care will involve discussion with patients about the risk of relapse and, for 
some patients, the framing of depression as a potentially chronic, on-going illness 
rather than something that can be “cured”. Do patients want to have these discussions 
and is relapse something that concerns people with a lived experience of depression? 
Are such discussions required for all patients following a first episode of depression? 
How do clinicians decide when to adopt a chronic disease model of depression 
management and for which people aiming towards a more definitive treatment might 
be appropriate?  Patient expectations and understanding may affect outcomes and so 
these are important questions to consider. 
The majority of existing research addressing patient preferences has been in the 
context of discussions around antidepressants, with fear of relapse recognised as a 
barrier to patients discontinuing antidepressant medication (16) and some patients 
confusing relapse with discontinuation symptoms (17). Research has also shown that 
patients may not have full confidence in the GPs’ ability to discuss discontinuation of 
antidepressants due to a perceived lack of knowledge and time (18). Interestingly, 
GPs felt that they did have sufficient knowledge to manage continuation therapy and 
would be more inclined to continue antidepressant medication in patients with a 
history of relapse (18). They did agree, however, that time constraints and a lack of 
evidence-based guidance on long-term depression management resulted in some 
patients being sub-optimally managed (18). 
Another consideration is whether the results of risk predictions can be used and 
shared in a clear and helpful manner and result in improved outcomes or lower costs 
when applied. To be useful in practice, prognostic models must include unambiguous 
prognostic factors, address a common and important problem and have face validity 
(doctors must trust a model to guide their practice rather than their own experience) 
(19). It is possible that a statistical prediction tool aligns too closely with a biomedical 
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model of depression that does not fully describe the course of depression in many 
patients. It may be that, for some patients, we should be aiming to “minimise relapse” 
or “prolong remission” rather than to set the unrealistic goal of preventing relapse 
altogether. At the same time we recognise that, due to limitations imposed by the 
healthcare system, GPs must gather and synthesise information to aid clinical 
decision-making in a relatively short amount of time and a prognostic model could 
facilitate the identification and stratification of these different risk groups. The views 
and preferences of patients, healthcare professionals and commissioners certainly 
need to be more robustly explored.
We hope that this editorial will encourage GPs to reflect on how relapse is currently 
discussed in consultations with a patient with depression. We highlight the need for 
further research into risk-stratification and more effective relapse prevention for 
people with depression managed in primary care. 
1. World Health Organization (WHO). (2017). Depression and Other Common 
Mental Disorders: Global Health Estimates. Available: 
https://www.who.int/mental_health/management/depression/prevalence_global
_health_estimates/en/ (accessed 4 Jun 2019)
2. Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. (2009). 
Recent trends in the incidence of recorded depression in primary care. Br J 
Psychiatry. 195(6): 520–4. 
3. Beshai S, Dobson KS, Bockting CLH, Quigley L. (2011) Relapse and 
recurrence prevention in depression: Current research and future prospects. 
Clin Psychol Rev. 31(8):1349–60.
4. Kupfer DJ. (1991). Long-term treatment of depression. J Clin Psychiatry. 
52:28–34.
5. Clark DM. (2011). Implementing NICE guidelines for the psychological 
treatment of depression and anxiety disorders: The IAPT experience. Int Rev 
Psychiatry. 23(4):318–27. 
Page 5 of 7
https://mc04.manuscriptcentral.com/bjgp
































































6. Ali S, Rhodes L, Moreea O, McMillan D, Gilbody S, Leach C, et al. (2017). 
How durable is the effect of low intensity CBT for depression and anxiety? 
Remission and relapse in a longitudinal cohort study. Behav Res Ther. 94:1–8.
7. Kendler KS, Thornton LM, Gardner CO. (2000). Stressful life events and 
previous episodes in the etiology of major depression in woman: an evaluation 
of the "kindling" hypothesis. Am J Psychiatry. 157(8):1243–51.
8. Gili M, Vicens C, Roca M, Andersen P, McMillan D. (2015). Interventions for 
preventing relapse or recurrence of depression in primary health care settings: 
A systematic review. Prev Med. 76(S):S16–21.
9. National Institute for Health and Care Excellence (NICE). (2018). Depression 
in adults: treatment and management guideline second consultation. Available: 
https://www.nice.org.uk/guidance/gid-cgwave0725/documents/html-content-2 
(accessed 28 Apr 2019)
10. National Institute for Health and Care Excellence (NICE). (2009). Depression 
in adults: recognition and management. CG90. 
http://www.nice.org.uk/guidance/cg90 (accessed 28 Apr 2019) 
11. Mental Health Taskforce. (2016). Five Year Forward View for Mental Health. 
Available: https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-
Health-Taskforce-FYFV-final.pdf (accessed 29 Apr 2019)
12. Riley RD, van der Windt D, P C, Moons K. (2019). Prognosis Research in 
Healthcare: Concepts, Methods, and Impact. First edit. Oxford University 
Press.
13. Buckman JEJ, Underwood A, Clarke K, Saunders R, Hollon SD, Fearon P. 
(2018). Risk factors for relapse and recurrence of depression in adults and how 
they operate: A four-phase systematic review and meta-synthesis. Clin Psychol 
Rev. 64:13–38.
14. Royston P, Moons KGM, Altman DG, Vergouwe Y. (2009). Prognosis and 
prognostic research: Developing a prognostic model. BMJ. r 31;338:b604. 
http://www.bmj.com/content/338/bmj.b604.abstract
Page 6 of 7
https://mc04.manuscriptcentral.com/bjgp
































































15. Altman DG, Vergouwe Y, Royston P, Moons KGM. (2009). Prognosis and 
prognostic research: Validating a prognostic model. BMJ. 338(7708):1432–5.
16. Maund E, Dewar-Haggart R, Williams S, Bowers H, Geraghty AWA, Leydon 
G, et al. (2019). Barriers and facilitators to discontinuing antidepressant use: A 
systematic review and thematic synthesis. J Affect Disord. 245:38–62.
17. Leydon GM, Rodgers L, Kendrick T. (2007). A qualitative study of patient 
views on discontinuing long-term selective serotonin reuptake inhibitors. 
Family Practice. 24(6):570–5.
18. Bosman RC, Huijbregts KM, Verhaak PF, Ruhé HG, van Marwijk HW, van 
Balkom AJ, et al. (2016). Long-term antidepressant use: a qualitative study on 
perspectives of patients and GPs in primary care. Br J Gen Pract. 
66(651):e708–19.
19. Moons KGM, Altman DG, Vergouwe Y, Royston P. (2009). Prognosis and 
prognostic research: application and impact of prognostic models in clinical 
practice. BMJ. 338:b606.
Page 7 of 7
https://mc04.manuscriptcentral.com/bjgp
British Journal of General Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
